Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction.

摘要: Posttransplantation hypertension has been identified as an independent risk factor for chronic allograft dysfunction and loss. Based on available morbidity mortality data, posttransplantation must be managed appropriately. During the past decade, calcium channel blockers have recommended by some antihypertensive agents of choice in this population, because it was theorized that their vasodilatory effects would counteract vasoconstrictive calcineurin inhibitors. With increasing data becoming available, reexamining use traditional agents, including diuretics beta-blockers, or newer angiotensin-converting enzyme (ACE) inhibitors angiotensin II receptor blockers, may beneficial. Transplant clinicians choose will provide patients with maximum benefit, from both a renal cardiovascular perspective. Beta-blockers, diuretics, ACE all demonstrated significant benefit disease. Calcium shown to possess ability cyclosporine-induced nephrotoxicity. When compared inhibitors, however, relative events is increased blockers. long-term benefits kidney unknown negative profile, these are best reserved adjunctive therapy